Arcus Biosciences Ownership | Who Owns Arcus Biosciences?

Overview Forecast RevenueFinancials Chart Transcripts

Arcus Biosciences Ownership Summary

Arcus Biosciences is owned by 98.41% institutional investors, 28.80% insiders. Gilead sciences is the largest institutional shareholder, holding 25.06% of RCUS shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 4.15% of its assets in Arcus Biosciences shares.

RCUS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Arcus Biosciences	98.41%	28.80%	-27.20%
Sector	Healthcare Stocks	244.59%	12.11%	-156.70%
Industry	Biotech Stocks	379.61%	11.70%	-291.31%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Gilead sciences	31.42M	25.06%	$968.83M
Blackrock funding, inc. /de	16.42M	13.09%	$506.11M
Blackrock	9.76M	11.33%	$148.69M
Vanguard group	7.96M	7.48%	$189.76M
State street	6.03M	4.81%	$185.89M
Wellington management group llp	5.90M	4.70%	$181.76M
Suvretta capital management	4.78M	3.81%	$147.26M
Fmr	4.05M	3.23%	$124.85M
Vanguard capital management	3.89M	3.10%	$119.88M
Citadel advisors	3.14M	2.50%	$96.65M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Gilead sciences	31.42M	58.76%	$968.83M
Invus financial advisors	1.61M	27.51%	$24.55M
Parkman healthcare partners	919.27K	2.90%	$28.34M
Suvretta capital management	4.78M	2.69%	$147.26M
Dafna capital management	441.83K	2.60%	$13.62M
Sectoral asset management	110.87K	2.39%	$3.42M
Decheng capital	464.78K	1.96%	$14.33M
Patient square capital lp	355.80K	1.70%	$10.97M
Ikarian capital	504.56K	1.68%	$15.56M
Siren	2.42M	1.51%	$74.62M

Top Buyers

Holder	Shares	% Assets	Change
Fmr	4.05M	0.01%	2.88M
Citadel advisors	3.14M	0.01%	1.81M
Vanguard group	7.96M	0.00%	1.33M
Blackrock funding, inc. /de	16.42M	0.01%	1.19M
Sixth street partners management company	941.76K	0.00%	941.76K

Top Sellers

Holder	Shares	% Assets	Change
Marshall wace, llp	1.95M	0.05%	-1.82M
Toronto dominion bank	-	-	-1.48M
Franklin resources	-	-	-853.49K
Braidwell lp	-	-	-802.10K
Woodline partners lp	3.01M	0.29%	-770.00K

New Positions

Holder	Shares	% Assets	Change	Value
Sixth street partners management company	941.76K	0.00%	941.76K	$29.03M
Ikarian capital	504.56K	1.68%	504.56K	$15.56M
Vestal point capital, lp	250.00K	0.15%	250.00K	$3.40M
Axa investment managers	232.67K	0.01%	232.67K	$3.16M
Boothbay fund management	154.26K	0.06%	154.26K	$4.76M

Sold Out

Holder	Change
Dinuzzo private wealth	-1.00
Advisory services network	-3.00
Tortoise investment management	-3.00
Sbi securities	-4.00
Sjs investment consulting	-5.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	236	6.79%	123,401,877	3.63%	98	0.80%	136	13.33%	61	10.91%
Mar 31, 2026	103	-53.81%	50,549,987	-58.37%	47	0.36%	50	-66.22%	28	-22.22%
Dec 31, 2025	136	-30.96%	84,869,998	-15.65%	79	0.89%	89	-11.00%	20	-62.96%
Sep 30, 2025	191	4.37%	99,188,061	2.60%	93	1.13%	96	-4.95%	52	6.12%
Jun 30, 2025	189	-	99,642,989	2.55%	93	0.96%	105	-17.32%	51	70.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
iShares Core S&P Small-Cap ETF	5.28M	4.15%	-6.08K
Vanguard Health Care Inv	3.45M	2.71%	-679.03K
Vanguard Morn Total Stk Mkt Idx Investor	2.80M	2.23%	-5.01K
Vanguard Total Stock Mkt Idx Inv	2.80M	2.23%	-5.01K
Vanguard MStar Total Stk Mkt Idx Invest	2.81M	2.21%	13.14K
State Street® SPDR® S&P® Biotech ETF	2.54M	2.00%	5.83K
iShares Russell 2000 ETF	2.26M	1.77%	-40.13K
Vanguard US Total Market Shares ETF	1.62M	1.53%	-
SPDR® S&P Biotech ETF	1.20M	1.13%	2.69K
Fidelity Select Health Care	949.76K	0.90%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 21, 2026	Azoy Alexander	Chief Accounting Officer	Sell	$84.81K
Jul 10, 2026	Jaen Juan C.	President	Sell	$7.88K
Jul 09, 2026	Jaen Juan C.	President	Sell	$1.46M
Jul 10, 2026	Jaen Juan C.	President	Sell	$566.41K
Jun 23, 2026	Jaen Juan C.	President	Sell	$389.48K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	6
2026 Q1	-	3
2025 Q4	-	31
2025 Q3	-	2
2025 Q2	-	-

RCUS Ownership FAQ

Who Owns Arcus Biosciences?

Arcus Biosciences shareholders are primarily institutional investors at 98.41%, followed by 28.80% insiders and -27.21% retail investors. The average institutional ownership in Arcus Biosciences's industry, Biotech Stocks , is 379.61%, which Arcus Biosciences falls below.

Who owns the most shares of Arcus Biosciences?

Arcus Biosciences’s largest shareholders are Gilead sciences (31.42M shares, 25.06%), Blackrock funding, inc. /de (16.42M shares, 13.09%), and Blackrock (9.76M shares, 11.33%). Together, they hold 49.48% of Arcus Biosciences’s total shares outstanding.

Does Blackrock own Arcus Biosciences?

Yes, BlackRock owns 11.33% of Arcus Biosciences, totaling 9.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 148.69M$. In the last quarter, BlackRock decreased its holdings by -137K shares, a -1.39% change.

Who is Arcus Biosciences’s biggest shareholder by percentage of total assets invested?

Gilead sciences is Arcus Biosciences’s biggest shareholder by percentage of total assets invested, with 58.76% of its assets in 31.42M Arcus Biosciences shares, valued at 968.83M$.

Who is the top mutual fund holder of Arcus Biosciences shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Arcus Biosciences shares, with 4.15% of its total shares outstanding invested in 5.28M Arcus Biosciences shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools